Aripiprazole Accord

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

aripiprazola

Available from:

Accord Healthcare S.L.U.

ATC code:

N05AX12

INN (International Name):

aripiprazole

Therapeutic group:

Psycholeptics

Therapeutic area:

Schizophrenia; Bipolar Disorder

Therapeutic indications:

Aripiprazolni sporazum je indiciran za liječenje shizofrenije kod odraslih i adolescenata starijih od 15 godina. Арипипразол ugovora naznačeno za liječenje od umjerenih do teških maničnih epizoda kada je bipolarni poremećaj poremećaj i za prevenciju novog manic epizoda kod odraslih, koji su doživjeli pretežno manične epizode, a čiji je manične epizode odgovorio na арипипразол u liječenju. Арипипразол pristanka indiciran za liječenje do 12 tjedana umjerenih i teških maničnih epizoda u bipolarni poremećaj kod adolescenata u dobi od 13 godina i stariji.

Product summary:

Revision: 15

Authorization status:

odobren

Authorization date:

2015-11-15

Patient Information leaflet

                                45
B. UPUTA O LIJEKU
46
UPUTA O LIJEKU: INFORMACIJE ZA KORISNIKA
ARIPIPRAZOL ACCORD 5 MG TABLETE
ARIPIPRAZOL ACCORD 10 MG TABLETE
ARIPIPRAZOL ACCORD 15 MG TABLETE
ARIPIPRAZOL ACCORD 30 MG TABLETE
aripiprazol
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE UZIMATI OVAJ
LIJEK
JER SADRŽI VAMA VAŽNE
PODATKE.
•
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
•
Ako imate dodatnih pitanja, obratite se svom liječniku ili
ljekarniku.
•
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
•
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika ili ljekarnika. To uključuje
i svaku moguću nuspojavu koja nije navedena u ovoj uputi. Pogledajte
dio 4.
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je Aripiprazol Accord i za što se koristi
2.
Što morate znati prije nego počnete uzimati Aripiprazol Accord
3.
Kako uzimati Aripiprazol Accord
4.
Moguće nuspojave
5
Kako čuvati Aripiprazol Accord
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE ARIPIPRAZOL ACCORD I ZA ŠTO SE KORISTI
Aripiprazol Accord sadrži djelatnu tvar aripiprazol i pripada skupini
lijekova koji se zovu
antipsihotici. Koristi se za liječenje odraslih i adolescenata u dobi
od 15 ili više godina koji boluju od
bolesti karakterizirane simptomima kao što su da bolesnik čuje vidi
ili osjeća stvari kojih nema,
sumnjičavost, pogrešno vjerovanje, nepovezan govor i ponašanje te
emocionalna tupost. Osobe s
ovom bolešću također mogu osjećati depresiju, krivnju, tjeskobu
ili napetost.
Ovaj se lijek koristi za liječenje odraslih osoba te adolescenata u
dobi od 13 i više godina koji boluju
od stanja čiji su simptomi „povišeno“ raspoloženje, pretjerana
količina energije, potreba za manjom
količinom sna nego obično, vrlo brz govor i ubrzan tijek misli te
ponekad teška razdražljivost. Također
sprječava povratak takvog stanja u odraslih bolesnika koji su
prethodno imali odgovor na terapiju
ovim lijekom.
2.
ŠTO MORA
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Aripiprazol Accord 5 mg tablete
Aripiprazol Accord 10 mg tablete
Aripiprazol Accord 15 mg tablete
Aripiprazol Accord 30 mg tablete
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Aripiprazol Accord 5 mg tablete
Jedna tableta sadrži 5 mg aripiprazola.
Pomoćna tvar s poznatim učinkom
Jedna tableta od 5 mg sadrži 63 mg laktoze (u obliku hidrata).
Aripiprazol Accord 10 mg tablete
Jedna tableta sadrži 10 mg aripiprazola.
Pomoćna tvar s poznatim učinkom
Jedna tableta od 10 mg sadrži 59 mg laktoze (u obliku hidrata).
Aripiprazol Accord 15 mg tablete
Jedna tableta sadrži 15 mg aripiprazola.
Pomoćna tvar s poznatim učinkom
Jedna tableta od 15 mg sadrži 88 mg laktoze (u obliku hidrata).
Aripiprazol Accord 30 mg tablete
Jedna tableta sadrži 30 mg aripiprazola.
Pomoćna tvar s poznatim učinkom
Jedna tableta od 30 mg sadrži 177 mg laktoze (u obliku hidrata).
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Tableta.
Aripiprazol Accord 5 mg tablete
Plave, bikonveksne neobložene tablete modificiranog pravokutnog
oblika duge oko 8,1 mm i široke
oko 4,6 mm s utisnutom oznakom „A5“ na jednoj strani i bez oznake
na drugoj strani.
Aripiprazol Accord 10 mg tablete
Ružičaste, bikonveksne neobložene tablete modificiranog pravokutnog
oblika duge oko 8,1 mm i
3
široke oko 4,6 mm s utisnutom oznakom „A10“ na jednoj strani i
bez oznake na drugoj strani.
Aripiprazol Accord 15 mg tablete
Žute, okrugle, bikonveksne neobložene tablete ukošene na rubovima,
promjera oko 7,14 mm s
utisnutom oznakom „A15“ na jednoj strani i bez oznake na drugoj
strani.
Aripiprazol Accord 30 mg tablete
Ružičaste, okrugle, bikonveksne neobložene tablete ukošene na
rubovima, promjera oko 9,1 mm s
utisnutom oznakom „A30“ na jednoj strani i bez oznake na drugoj
strani.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
Aripiprazol Accord je indiciran za liječenje shizofrenije u odraslih
i adolescenata u dobi od 15 i više
godina.
Aripiprazol Accord je in
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 03-11-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 03-11-2022
Public Assessment Report Public Assessment Report Bulgarian 27-11-2015
Patient Information leaflet Patient Information leaflet Spanish 03-11-2022
Public Assessment Report Public Assessment Report Spanish 27-11-2015
Patient Information leaflet Patient Information leaflet Czech 03-11-2022
Public Assessment Report Public Assessment Report Czech 27-11-2015
Patient Information leaflet Patient Information leaflet Danish 03-11-2022
Public Assessment Report Public Assessment Report Danish 27-11-2015
Patient Information leaflet Patient Information leaflet German 03-11-2022
Public Assessment Report Public Assessment Report German 27-11-2015
Patient Information leaflet Patient Information leaflet Estonian 03-11-2022
Public Assessment Report Public Assessment Report Estonian 27-11-2015
Patient Information leaflet Patient Information leaflet Greek 03-11-2022
Public Assessment Report Public Assessment Report Greek 27-11-2015
Patient Information leaflet Patient Information leaflet English 03-11-2022
Public Assessment Report Public Assessment Report English 27-11-2015
Patient Information leaflet Patient Information leaflet French 03-11-2022
Public Assessment Report Public Assessment Report French 27-11-2015
Patient Information leaflet Patient Information leaflet Italian 03-11-2022
Public Assessment Report Public Assessment Report Italian 27-11-2015
Patient Information leaflet Patient Information leaflet Latvian 03-11-2022
Public Assessment Report Public Assessment Report Latvian 27-11-2015
Patient Information leaflet Patient Information leaflet Lithuanian 03-11-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 03-11-2022
Public Assessment Report Public Assessment Report Lithuanian 27-11-2015
Patient Information leaflet Patient Information leaflet Hungarian 03-11-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 03-11-2022
Public Assessment Report Public Assessment Report Hungarian 27-11-2015
Patient Information leaflet Patient Information leaflet Maltese 03-11-2022
Public Assessment Report Public Assessment Report Maltese 27-11-2015
Patient Information leaflet Patient Information leaflet Dutch 03-11-2022
Public Assessment Report Public Assessment Report Dutch 27-11-2015
Patient Information leaflet Patient Information leaflet Polish 03-11-2022
Public Assessment Report Public Assessment Report Polish 27-11-2015
Patient Information leaflet Patient Information leaflet Portuguese 03-11-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 03-11-2022
Public Assessment Report Public Assessment Report Portuguese 27-11-2015
Patient Information leaflet Patient Information leaflet Romanian 03-11-2022
Public Assessment Report Public Assessment Report Romanian 27-11-2015
Patient Information leaflet Patient Information leaflet Slovak 03-11-2022
Public Assessment Report Public Assessment Report Slovak 27-11-2015
Patient Information leaflet Patient Information leaflet Slovenian 03-11-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 03-11-2022
Public Assessment Report Public Assessment Report Slovenian 27-11-2015
Patient Information leaflet Patient Information leaflet Finnish 03-11-2022
Public Assessment Report Public Assessment Report Finnish 27-11-2015
Patient Information leaflet Patient Information leaflet Swedish 03-11-2022
Public Assessment Report Public Assessment Report Swedish 27-11-2015
Patient Information leaflet Patient Information leaflet Norwegian 03-11-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 03-11-2022
Patient Information leaflet Patient Information leaflet Icelandic 03-11-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 03-11-2022

Search alerts related to this product